New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
Daxor (DXR) announced significant research findings at the American College of Cardiology's 74th Annual Scientific Session, demonstrating improved survival rates in heart failure patients using their blood volume analysis (BVA) technology. The study, conducted by Minneapolis Heart Institute Foundation and Allina Health, analyzed 1,237 heart failure patients, with 202 receiving BVA testing near discharge.
Key findings revealed that patients confirmed as 'euvolemic' (normal blood volume) through BVA showed 2.61 times better survival rates compared to hypervolemic (congested) patients. The study demonstrated a strong statistical significance (p=0.002), and the correlation between blood volume status and survival persisted even after adjusting for comorbidities.
Daxor (DXR) ha annunciato risultati di ricerca significativi durante la 74ª Sessione Scientifica Annuale dell'American College of Cardiology, dimostrando un miglioramento dei tassi di sopravvivenza nei pazienti con insufficienza cardiaca grazie alla loro tecnologia di analisi del volume ematico (BVA). Lo studio, condotto dalla Minneapolis Heart Institute Foundation e Allina Health, ha analizzato 1.237 pazienti con insufficienza cardiaca, di cui 202 hanno effettuato il test BVA in prossimità della dimissione.
I risultati principali hanno evidenziato che i pazienti confermati come 'euvolemici' (volume ematico normale) tramite BVA hanno mostrato tassi di sopravvivenza 2,61 volte superiori rispetto ai pazienti ipervolemici (congesti). Lo studio ha evidenziato una forte significatività statistica (p=0,002) e la correlazione tra lo stato del volume ematico e la sopravvivenza è rimasta valida anche dopo aver considerato le comorbidità.
Daxor (DXR) anunció hallazgos significativos en investigación durante la 74ª Sesión Científica Anual del American College of Cardiology, demostrando mejores tasas de supervivencia en pacientes con insuficiencia cardíaca mediante su tecnología de análisis del volumen sanguíneo (BVA). El estudio, realizado por la Minneapolis Heart Institute Foundation y Allina Health, analizó a 1,237 pacientes con insuficiencia cardíaca, de los cuales 202 se sometieron a la prueba BVA cerca del alta hospitalaria.
Los hallazgos clave revelaron que los pacientes confirmados como 'euvolemicos' (volumen sanguíneo normal) mediante BVA mostraron tasas de supervivencia 2.61 veces mayores en comparación con los pacientes hipervolémicos (congestivos). El estudio demostró una fuerte significancia estadística (p=0.002), y la correlación entre el estado del volumen sanguíneo y la supervivencia persistió incluso después de ajustar por comorbilidades.
Daxor (DXR)는 미국심장학회(ACC) 제74회 연례 과학 세션에서 중요한 연구 결과를 발표하며, 혈액량 분석(BVA) 기술을 사용한 심부전 환자의 생존율 향상을 입증했습니다. 미니애폴리스 심장 연구소 재단과 알리나 헬스가 수행한 이 연구는 1,237명의 심부전 환자를 분석했으며, 그중 202명은 퇴원 직전 BVA 검사를 받았습니다.
주요 결과에 따르면, BVA를 통해 '유혈량 정상'(euvolemic)으로 확인된 환자들은 과혈량 상태(울혈)인 환자에 비해 2.61배 높은 생존율을 보였습니다. 연구는 강력한 통계적 유의성(p=0.002)을 나타냈으며, 혈액량 상태와 생존율 간의 상관관계는 동반 질환을 보정한 후에도 유지되었습니다.
Daxor (DXR) a annoncé des résultats de recherche importants lors de la 74e session scientifique annuelle de l'American College of Cardiology, démontrant une amélioration des taux de survie chez les patients insuffisants cardiaques grâce à leur technologie d'analyse du volume sanguin (BVA). L'étude, menée par la Minneapolis Heart Institute Foundation et Allina Health, a analysé 1 237 patients souffrant d'insuffisance cardiaque, dont 202 ont bénéficié d'un test BVA peu avant leur sortie.
Les résultats clés ont révélé que les patients confirmés comme « euvolémiques » (volume sanguin normal) via la BVA présentaient des taux de survie 2,61 fois supérieurs à ceux des patients hypervolémiques (congestifs). L'étude a démontré une forte signification statistique (p=0,002), et la corrélation entre l'état du volume sanguin et la survie est restée valable même après ajustement pour les comorbidités.
Daxor (DXR) gab bedeutende Forschungsergebnisse auf der 74. Jahrestagung des American College of Cardiology bekannt, die verbesserte Überlebensraten bei Herzinsuffizienzpatienten durch den Einsatz ihrer Blutvolumen-Analyse (BVA)-Technologie zeigen. Die Studie, durchgeführt von der Minneapolis Heart Institute Foundation und Allina Health, analysierte 1.237 Herzinsuffizienzpatienten, von denen 202 kurz vor der Entlassung einen BVA-Test erhielten.
Die wichtigsten Ergebnisse zeigten, dass Patienten, die mittels BVA als 'euvolemisch' (normales Blutvolumen) bestätigt wurden, 2,61-mal bessere Überlebensraten im Vergleich zu hypervolämischen (stauungsbedingten) Patienten aufwiesen. Die Studie zeigte eine starke statistische Signifikanz (p=0,002), und der Zusammenhang zwischen Blutvolumenstatus und Überleben blieb auch nach Anpassung für Begleiterkrankungen bestehen.
- BVA testing shows 2.61x better survival rates for euvolemic patients
- Strong statistical significance with p-value of 0.002
- Study validates BVA technology's effectiveness with large sample size (1,237 patients)
- Results demonstrate direct correlation between blood volume status and survival outcomes
- None.
Insights
The research presented at ACC25 represents significant clinical validation for Daxor's Blood Volume Analysis (BVA) technology in heart failure management. A hazard ratio of
This study builds critical evidence for BVA as a discharge decision-making tool in cardiology practices. Heart failure is a leading cause of hospital readmissions, with approximately 25% of patients readmitted within 30 days of discharge, costing the healthcare system
The multi-center nature of this study (Minneapolis Heart Institute Foundation and Allina Health) and substantial sample size (1,237 patients) enhance credibility. However, challenges remain: determining whether this evidence is sufficient to change established clinical practices, securing expanded reimbursement coverage, and integrating BVA into standard discharge protocols.
Most importantly, this study addresses a critical unmet need - objective measurement of volume status before discharge. Current methods rely heavily on subjective clinical assessment, which this data suggests may be insufficient. This positions Daxor's technology as potentially practice-changing in a high-cost, high-volume healthcare segment.
This clinical validation strengthens Daxor's market position in the cardiovascular diagnostics space. The 2.61x survival benefit demonstrated in this large study provides compelling evidence that could accelerate BVA adoption among cardiologists and hospitals specializing in heart failure management.
With Daxor's market cap at just
The presentation at ACC25, one of cardiology's premier conferences, provides excellent visibility to key decision-makers. The strong endorsement from the Minneapolis Heart Institute Foundation adds institutional credibility that could influence purchasing decisions.
Revenue impact will depend on: 1) conversion of clinical evidence to standard-of-care guidelines, 2) reimbursement expansion, and 3) sales execution. While the timeline for full commercial impact remains uncertain, this validation addresses a fundamental question about BVA's clinical utility.
The technology's ability to identify high-risk patients before discharge represents a compelling value proposition in an era focused on reducing readmissions and improving outcomes. This positions BVA as both a clinical and economic tool that could drive adoption despite Daxor's relatively small size in the medical device landscape.
Precise Volume Measurement Prior to Discharge Identifies Mortality Risk
Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data presented at the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. Research from The Minneapolis Heart Institute Foundation® and Allina Health Minneapolis Heart Institute® demonstrated that hospitalized heart failure patients who received blood volume analysis (BVA) prior to hospital discharge could be used to stratify those with a substantially better survival rate.
The study, "Radiolabeled Blood Volume Analysis during Hospitalization for Acute Decompensated Heart Failure and 1-Year Mortality," presented by Hailey Miedema, research intern, Minneapolis Heart Institute Foundation, evaluated 1,237 hospitalized heart failure patients, including 202 who underwent BVA testing within two days of discharge.
Key findings:
- Patients confirmed as "euvolemic" (normal blood volume) through BVA showed markedly improved one-year survival rates
- In a Kaplan-Meier survival study, a hazard ratio, the risk of the event (in this case, death), is 2.61 times higher in the control group who were hypervolemic (congested) compared to the euvolemic group which BVA could uniquely identify
- This clinically significant hazard ratio quantifies survival differences across the entire follow-up period, accounting for both event occurrence and timing and had a very strong statistically significant p-value of 0.002
- The direct correlation between blood volume status and survival outcomes persisted even after adjusting for comorbidities
- Results strongly support the clinical value of objective blood volume measurement before discharging patients with acute decompensated heart failure to ensure successful treatment to euvolemia which only the BVA test was able to determine
Co- investigator Peter M. Eckman, MD, researcher at the Minneapolis Heart Institute Foundation and cardiologist and heart failure section head at the Allina Health Minneapolis Heart Institute, stated, "BVA is a great tool to ensure proper decongestion before discharge. This research indicates heart failure patients who achieve BVA-measured euvolemia experience higher one-year survival compared to those with hypervolemia."
"These findings represent a significant advancement in heart failure management and are consistent with numerous prior studies regarding the benefit of BVA in heart failure care" said John L. Jefferies, MD, MBA, MPH, Chief Medical Officer, Daxor Corporation. "By objectively measuring blood volume status before discharge, we can now identify patients at higher risk and optimize their treatment accordingly. This study validates what we've long believed—that precision volume management guided by BVA technology saves lives and improves outcomes for heart failure patients."
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What are the survival benefits of Daxor's BVA technology for heart failure patients?
How many patients were included in the DXR blood volume analysis study?
What is the statistical significance of DXR's BVA study results?
How does Daxor's BVA technology help in heart failure patient management?
When was the DXR blood volume analysis research presented?
